In a significant move to accelerate its transition from an upstream chemical supplier to a downstream consumer-facing healthcare brand, Citi Pharma has officially received clearance from the Competition Commission of Pakistan (CCP) to acquire 100% of Pakheim International Pharma (Private) Limited. The acquisition, formally disclosed to the Pakistan Stock Exchange (PSX) this month, marks a crucial turning point for the Lahore-based ingredients manufacturer.
While the financial terms of the transaction were not disclosed, regulatory filings indicate that the two companies signed a share purchase agreement on May 6, 2026, the same day Citi’s board approved the deal. Citi Pharma has stated it will fund the acquisition through a mix of internal cash reserves and existing bank facilities, with all payments scheduled to be completed by December 31, 2026.
Accelerating the Brand Portfolio
The rationale behind the acquisition lies in Pakheim International’s established market position. While Pakheim is relatively small—generating an estimated annual revenue of approximately Rs500 million compared to Citi Pharma’s Rs14 billion revenue for the year ending June 30, 2026—it brings a valuable portfolio of 63 branded pharmaceutical products.
For Citi Pharma, which has historically operated as a major B2B supplier of Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates, this acquisition provides instant access to a diversified, ready-to-market product line. Rather than investing years in R&D, clinical trials, and regulatory approvals to build its own consumer brands from scratch, acquiring Pakheim allows Citi to immediately enter the finished goods market.
Also Read: Gul Ahmed Textile Mills Approves 43.75-Acre Land Acquisition and Major Renewable Energy Projects
Citi Pharma has built a dominant position in the domestic market as a key manufacturer of paracetamol. However, the API market is typically characterised by high volumes and lower profit margins compared to branded, finished medicines. The acquisition of Pakheim is a direct strategic response to this, enabling Citi to capture more value across the pharmaceutical supply chain. By controlling the entire process—from synthesising the raw material to manufacturing and marketing the final branded tablet—Citi aims to significantly improve its overall profitability.
This vertical integration strategy is becoming increasingly common within Pakistan’s pharmaceutical sector as companies look to mitigate supply chain disruptions and leverage domestic manufacturing capabilities.
The CCP, in an order dated October 9, reviewed the proposed transaction and found that it “does not raise competition concerns,” clearing the path for the merger. While regulatory approval is a major hurdle cleared, Citi noted that the final completion of the acquisition remains subject to the satisfaction of other customary legal and regulatory formalities.